Mode
Text Size
Log in / Sign up
N/A N=100 Randomized Double-blind Other

Anaesthesia for Laparoscopic Sleeve Gastrectomy

Obese

Enrolled (actual)
100
Serious AEs
0.0%
Results posted
Sep 2020
Primary outcome: Primary: Analgesic Requirements. — 3.56; 1.67 mg

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Propofol (Drug); Remifentanil (Drug); Dexmedetomidine (Drug); Desflurane (Drug)
Age
Adult · 30+ yrs
Sex
All
Sponsor
Menoufia University
Primary completion
Mar 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Analgesic Requirements.
3.56; 1.67
SECONDARY
The Intra-operative Mean Arterial Blood Pressure.
71.05; 62.7

Summary

Background: Laparoscopic sleeve gastrectomy is commonly done with total intravenous anaesthesia (TIVA) or balanced anaesthesia using intravenous and an inhalation agent. It is still unclear which anaesthesia regimen is better for this group of patients. The present study was carried out to compare the use of inhalation anaesthesia technique using desflurane and TIVA using propofol and dexmedetomidine. Methods: This randomized controlled trial was carried out on 100 morbidly obese patients undergoing laparoscopic sleeve gastrectomy. The patients were randomized into two equal groups, inhalational group and TIVA group for anaesthesia maintenance. All patients received general anaesthesia and induced with propofol, remifentanil and cis-atracurium. In inhalation group, anaesthesia was maintained by desflurane in oxygen air mixture while in TIVA group anaesthesia was maintained by intravenous propofol and dexmedetomidine infusion. Intra-operative vital signs and anaesthesia recovery time were recorded. Post-operative nausea, vomiting, pain score, analgesic consumption, the onset of bowel movement, and post-anaesthetic care unit (PACU) stay were studied for both groups.

Eligibility Criteria

Inclusion Criteria

  • Morbid obese scheduled for sleeve gastrectomy.

Exclusion Criteria

  • Patients refusal and allergy to drugs used.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03029715). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search